Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review

• Published in: Research in social and administrative pharmacy 2022-07, Vol.18 (7), p.3079-3093
• Main Authors: Morris, Earl J., Hollmann, Josef, Hofer, Ann-Kathrin, Bhagwandass, Hemita, Oueini, Razanne, Adkins, Lauren E., Hallas, Jesper, Vouri, Scott M.
• Format: Article
• Language: English
• Subjects: Adverse drug events; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmacovigilance; Prescribing cascade; Prescription sequence symmetry analysis; Prescriptions
• ISSN: 1551-7411; 1934-8150
• DOI: 10.1016/j.sapharm.2021.08.003

The (prescription) sequence symmetry analysis (PSSA) design has been used to identify potential prescribing cascade signals by assessing the prescribing sequence of an index drug relative to a marker drug presumed to treat an adverse drug event provoked by the index drug. This review aimed to explore the use of the PSSA design as a pharmacovigilance tool with a particular focus on the breadth of identified signals and advances in PSSA methodology. We searched Embase, PubMed/Medline, Google Scholar, Web of Science and grey literature to identify studies that used the PSSA methodology. Two reviewers independently extracted relevant data for each included article. Study characteristics including signals identified, exposure time window, stratified analyses, and use of controls were extracted. We identified 53 studies which reported original results obtained using PSSA methodology or quantified the validity of components of the PSSA design. Of those, nine studies provided validation metrics showing reasonable sensitivity and high specificity of PSSA to identify prescribing cascade signals. We identified 340 unique index drug – marker drug signals published in the PSSA literature, representing 281 unique index – marker pharmacological class dyads (i.e., unique fourth-level Anatomical Therapeutic Chemical [ATC] classification dyads). Commonly observed signals were identified for index drugs acting upon the nervous system (34%), cardiovascular system (21%), and blood and blood-forming organs (15%), and many marker drugs were related to the nervous system (25%), alimentary tract and metabolism (23%), cardiovascular system (17%), and genitourinary system and sex hormones (14%). Negative controls and positive controls were utilized in 21% and 13% of studies, respectively. The PSSA methodology has been used in 53 studies worldwide to detect and evaluate over 300 unique prescribing cascades signals. Researchers should consider sensitivity analyses incorporating negative and/or positive controls and additional time windows to evaluate time-varying biases when designing PSSA studies. •The PSSA design is a pharmacovigilance tool to identify prescribing cascade signals.•Many signals linked to a wide array of organs have been identified using PSSA.•PSSA has shown moderate sensitivity and specificity in identifying adverse events.•Potential sources of time-varying confounding should be considered when using PSSA.•Consistent reporting of results is needed when disseminating